AMPK activator well tolerated, safe for NASH

Poxel SA announced positive results for the phase 2a trial of PXL770 for the treatment of nonalcoholic steatohepatitis, according to a press release.PXL770 is an oral direct adenosine monophosphate-activated protein kinase (AMPK) activator.“The underlying pathophysiological drivers of nonalcoholic fatty liver disease (NAFLD) and NASH are highly complex and support the need for development of novel therapies acting on different targets that can address a variety of key disease drivers,” Vlad Ratziu, MD, PhD, professor of hepatology at Sorbonne University and Pitié-SalpêtrièreRead More

Share on facebook
Share on twitter
Share on linkedin